Document:

<PAGE>

                                                                   Exhibit 10.18

                       CONFIDENTIAL TREATMENT REQUESTED.
           CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED
              AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.

                       COLLABORATIVE RESEARCH AGREEMENT
                       --------------------------------

     This COLLABORATIVE RESEARCH AGREEMENT ("Agreement") is entered into as of
December 28, 2000 by and between PFIZER INC, a Delaware corporation, having an
office at 235 East 42nd Street, New York, New York 10017 and its Affiliates
("Pfizer"), and XENOGEN BIOSCIENCES ("Xenogen Cranbury"), an Ohio Corporation,
with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned
subsidiary of Xenogen Corp. ("Xenogen").

                                   RECITALS
                                   --------

     WHEREAS, Pfizer wishes to develop Assays (as defined below) to use in
performing phenotypic analysis of Transgenic Animals (as defined below) with a
view toward identifying the role of interesting genes in human disease processes
and toward validating gene function in research animals; and

     WHEREAS, Pfizer has detailed protocols for individual Assays;

     WHEREAS, Xenogen Cranbury has expertise in developing and conducting such
Assays and in performing phenotypic analysis of Transgenic Animals using such
Assays; and

     WHEREAS, Xenogen Cranbury desires to collaborate with Pfizer on the
development of such Assay packages for Transgenic Animals;

     NOW, THEREFORE, in consideration of the promises and mutual covenants
contained herein, Xenogen Cranbury and Pfizer agree as follows:

1.   DEFINITIONS.
     -----------
          Whenever used in this Agreement, the terms defined in this Section 1
shall have the meanings specified.
<PAGE>

                                       2

     1.1  "Affiliate" means, with respect to Pfizer, any legal entity
           ---------
controlling, controlled by, or under common control with Pfizer; and with
respect to Xenogen Cranbury, any legal entity controlling, controlled by, or
under common control with Xenogen Cranbury; where, in all cases, "control" means
the ownership, directly or indirectly, of fifty percent (50%) or more of the
voting capital shares or similar voting securities of the other entity.

     1.2  "Area" means: (a) research to develop a battery of phenotypic and
           ----
challenge Assays on Transgenic Animals; (b) performing phenotypic analysis on
Transgenic Animals using such Assays; and (c) any other activities identified in
the course of the research or development hereunder; in all cases only as
specified in the Research Plan (as defined below).

     1.3  "Assay" means any of the Level I Assays, the Level II Assays, the
           -----
Level IIIP Assays, or the Level IIIXC Assays as defined below.

     1.4  "Contract Period" means the period beginning on the Effective Date and
           ---------------
ending on the date on which this Agreement terminates.

     1.5  "Contract Research Service" means a research service performed for a
           -------------------------
Third Party (as defined below) for a fee or other consideration.

     1.6  "Control Animal" means any mouse, other than a Transgenic Animal (as
           --------------
defined below), acquired by Xenogen Cranbury under this Agreement, including,
but not limited to: ***

     1.7  "Effective Date" means December 28, 2000.
           --------------

     1.8  "Level I Assay" means any assay identified as a Level I Assay in
           -------------
Exhibit B, as annexed hereto, or as the parties may from time to time identify
as a Level I Assay in a written amendment to the Research Plan.

     1.9  "Level II Assay" means any assay identified as a Level II Assay in
            --------------
Exhibit B, as annexed hereto, or as the parties may from time to time identify
as a Level II Assay in a written amendment to the Research Plan.

     1.10 "Level III Assay" means a Level IIIP Assay or a Level IIIXC Assay
           ---------------
(which may be collectively referred to as Level III Assays).

          1.10.1  "Level IIIP Assay" means any assay incorporating Pfizer
                   ----------------
Technology and Pfizer Confidential Information (both as defined below)
identified as a Level IIIP Assay in Exhibit B, as annexed hereto, or as the
parties may from time to time identify as a Level IIIP Assay in a written
amendment to the Research Plan.

_______________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       3

          1.10.2  "Level IIIXC Assay" means any assay incorporating Xenogen
                   -----------------
Cranbury Technology and Xenogen Cranbury Confidential Information (both as
defined below) identified as a Level IIIXC Assay in Exhibit B, as annexed
hereto, or as the parties may from time to time identify as a Level IIIXC Assay
in a written amendment to the Research Plan.  The designation of the Level IIIXC
Assay shall be at the sole discretion of Xenogen Cranbury and Level IIIXC Assay
will not be part of Program Technology.

     1.11 "Period of Exclusivity" means, with respect to any Level III Assay,
           ---------------------
the period ending on the second anniversary of the termination or expiration of
this Agreement.

     1.12 "Pfizer Compound" means any Pfizer compound, any library of Pfizer
           ---------------
compounds, and intermediates of any Pfizer compound, any impurities of any
Pfizer compound, and any information regarding the chemical or biochemical
properties of any Pfizer compound that Pfizer delivers to Xenogen Cranbury under
this Agreement.

     1.13 "Pfizer Confidential Information" means (a) all Results (as defined in
           -------------------------------
Section 1.19) and Program Technology, and (b) all other information about any
element of Pfizer Technology, including, without limitation, protocols, which
Pfizer discloses to Xenogen Cranbury and designates as "Confidential," where
such disclosure is either in writing or within 30 days of such disclosure Pfizer
provides Xenogen Cranbury a memorandum identifying the disclosure and
characterizing it as confidential.  Notwithstanding the foregoing, "Pfizer
Confidential Information" shall not include any information that (i) at the time
of disclosure to Xenogen Cranbury, is already known by Xenogen Cranbury other
than by virtue of a prior confidential disclosure to Xenogen Cranbury by Pfizer;
or (ii) is or becomes disclosed in published literature, or otherwise is or
becomes generally known to the public, in each case through no fault or omission
of Xenogen Cranbury; or (iii) is obtained by Xenogen Cranbury from a third party
free from any obligation of confidentiality to Pfizer.

     1.14 "Pfizer Technology" means (a) Technology developed prior to the
           -----------------
Effective Date by employees of, or consultants to, Pfizer acting alone or
jointly with third parties (but, in the case of consultants or third parties,
only to the extent Pfizer has the right to grant rights to such Technology), and
including without limitation any Transgenic Animals; (b) Program Technology; or
(c) Results.

     1.15 "Program Technology" means Technology developed, in the course of
           ------------------
performing the Research Program by employees of or consultants to Pfizer or
Xenogen Cranbury solely or jointly with each other, excluding Results and Level
<PAGE>

                                       4

IIIXC Assays, but including, without limitation, Level I, Level II and Level
IIIP Assays.

     1.16 "Research Plan" means the written plan describing the research and
           -------------
development in the Area to be carried out during the Contract Period by Pfizer
and Xenogen Cranbury pursuant to this Agreement. The Research Plan is attached
to and made a part of this Agreement as Exhibit A. The Research Plan may be
amended from time to time by agreement of the parties. Any such amended Research
Plan shall be appended hereto as an Exhibit.

     1.17 "Research Program" is the collaborative research program in the Area
           ----------------
conducted by Pfizer and Xenogen Cranbury pursuant to the Research Plan.

     1.18 "Results" means any data or information generated by either party in
           -------
the course of performing the Research Program, including, without limitation,
any data relating to the development and use of any Assay, and any data or
information resulting from the application of any Assay to any Transgenic Animal
or Control Animal.

     1.19 "Technology" means and includes all materials, technology, technical
           ----------
data and information, inventions, methods, know-how, expertise and trade secrets
within the Area.

     1.20 "Third Party" means any party other than Pfizer, Xenogen, or Xenogen
           -----------
Cranbury.

     1.21 "Transgenic Animal" means any genetically modified mouse supplied by
           -----------------
Pfizer to Xenogen Cranbury under this Agreement.

     1.22 "Xenogen Cranbury Technology" means Technology that is or was
           ---------------------------
developed by employees of, or consultants to, Xenogen Cranbury alone or jointly
with third parties prior to the Effective Date, but, in the case of consultants
or third parties, only to the extent Xenogen Cranbury has the right to grant
rights to such Technology, and specifically excluding, in all cases: (i) any
technology concerning or relating to in vivo imaging; and (ii) light-producing
cells, micro-organisms or animals; and (iii) other technologies intended for use
with (i) or (ii).

     1.23 "Xenogen Cranbury Confidential Information" means (a) all information
           -----------------------------------------
about any element of Xenogen Cranbury Technology which Xenogen Cranbury
discloses to Pfizer and designates as "Confidential," where such disclosure is
either in writing or within 30 days of such disclosure Xenogen Cranbury provides
Pfizer a memorandum identifying the disclosure and characterizing it as
confidential.  Notwithstanding the foregoing, "Xenogen Cranbury Confidential
Information" shall not include any information that (i) at the
<PAGE>

                                       5

time of disclosure to Pfizer, is already known by Pfizer other than by virtue of
a prior confidential disclosure to Pfizer by Xenogen Cranbury; or (ii) is or
becomes disclosed in published literature, or otherwise is or becomes generally
known to the public, in each case through no fault or omission of Pfizer; or
(iii) is obtained by Pfizer from a third party free from any obligation of
confidentiality to Xenogen Cranbury.

2.   COLLABORATIVE RESEARCH PROGRAM
     ------------------------------

     2.1  Purpose.  Xenogen Cranbury and Pfizer each shall conduct their
          -------
respective responsibilities of the Research Program throughout the Contract
Period.  The objective of the Research Program is to develop specific phenotypic
assays and to validate and test such assays on Transgenic Animals.

     2.2  Research Plan.  The initial Research Plan is described in the attached
          -------------
Exhibit A.  As the Research Plan is modified by mutual agreement of the parties,
the modified version shall be appended to Exhibit A and made part of this
Agreement.

     2.3  Research Committee
          ------------------

          2.3.1  Purpose.  Pfizer and Xenogen Cranbury shall establish a
                 -------
Research Committee (the "Research Committee"):

                 (a)  to review and evaluate progress under the Research Plan;

                 (b)  to prepare the Research Plan, and amendments and evaluate
                 the need for extensions to the Agreement;

                 (c)  to propose, discuss, select and document in writing, the
                 mutual acceptance of Assays in the Area to be included in the
                 Research Plan;

                 (d)  to coordinate and monitor publication as provided under
                 Section 4.7 of this Agreement, of Results (this function shall
                 survive termination of this Agreement for five (5) years); and

                 (e)  to designate Assays as either Level I, Level II, or Level
                 III.

          2.3.2  Membership.  Each of Pfizer and Xenogen Cranbury shall appoint,
                 ----------
in its sole discretion, three members to the Research Committee. Each party may
replace its respective Research Committee members at any time, with prior
written notice to the other party hereto.  The parties initially appoint the
following members:
<PAGE>

                                       6

     Pfizer Appointees:             ***

     Xenogen Cranbury Appointees:   ***

          2.3.3  Chair. The Research Committee shall be chaired by two co-
                 -----
chairpersons, one appointed by Pfizer and the other appointed by Xenogen
Cranbury.

          2.3.4  Meetings. The Research Committee shall meet at least quarterly,
                 --------
at places selected by each party in turn and on dates mutually agreed by the
parties. The location of the first meeting of the Research Committee shall be at
Pfizer's election. Representatives of Pfizer or Xenogen Cranbury or both, in
addition to members of the Research Committee, may attend such meetings at the
invitation of either party. Any materials to be submitted to the members of the
Research Committee shall be delivered to each member not less than five (5)
business days before the meeting.

          2.3.5  Minutes.  The Research Committee shall keep accurate minutes of
                 -------
its deliberations which record all proposed decisions and all actions
recommended or taken. Drafts of the minutes shall be delivered to all Research
Committee members within five (5) business days after each meeting. The party
choosing the location for the meeting shall be responsible for the preparation
and circulation of the draft minutes. Draft minutes shall be edited by the co-
chairpersons and shall be issued in final form only with their approval and
agreement.

          2.3.6  Decisions.  All decisions of the Research Committee shall be
                 ---------
made by mutual agreement except that Pfizer, in its sole discretion, shall
decide the overall direction of the Research Program.

          2.3.7  Expenses.   Pfizer and Xenogen Cranbury shall each bear all
                 --------
expenses, including reasonable travel, related to the participation of their
designated members of the Research Committee, respectively.

     2.4  Reports and Materials.
          ---------------------

          2.4.1  Reports.  During the Contract Period, Xenogen Cranbury shall
                 -------
furnish to the Research Committee:

          (a)    summary written reports within fifteen (15) days after the end
                 of each three-month period commencing on the
________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       7

                 Effective Date, describing the progress under the Research
                 Plan;

          (b)                 a comprehensive written report within thirty (30)
                 days after the end of the Contract Period, describing in detail
                 the work accomplished by it under the Research Plan during the
                 Contract Period and discussing and evaluating the results of
                 such work;

          (c)                 a written report describing the detailed protocols
                 of all assays developed under the Research Program;

          (d)                 a written report detailing Results. Such reports
                 will be submitted at the end of Phase 1A, 1B and Phase 2 of
                 Tracks I and II; and

          (e)                 any report containing information that Xenogen
                 Cranbury may generate using Level II Assays for Third Parties
                 during the Term, pursuant to Section 4.3.

          2.4.2 Materials.  During the Contract Period, each party shall provide
                ---------
the other, to the extent necessary for the receiving party to perform its
responsibilities under the Research Plan, with Transgenic Animals, Control
Animals, Pfizer Compounds, which are part of Pfizer Technology, Xenogen Cranbury
Technology or Program Technology.  Such supply of materials and Technology shall
be in accordance with the Research Plan, or as a party may otherwise reasonably
request from time to time and the other party agree to provide.  To the extent
that the quantities of materials requested and supplied by the parties exceed
the quantities required to be provided under the Research Plan, the requesting
party shall reimburse the other for the reasonable costs of such materials.
Each party shall use and store such materials in accordance with all applicable
laws and regulations, and shall exert due care in so doing.

     2.5  Laboratory Facilities and Personnel.  Xenogen Cranbury and Pfizer each
          -----------------------------------
shall provide laboratory facilities, equipment and personnel, in each case
suitable to the need, for carrying out the Research Program.

     2.6  Diligent Efforts.  Pfizer and Xenogen Cranbury each shall use
          ----------------
reasonably diligent efforts to achieve the objectives of the Research Program.
Xenogen Cranbury will use reasonably diligent efforts to achieve the objectives
listed in the Research Plan and Pfizer will use reasonably diligent efforts to
assist Xenogen Cranbury in such efforts.
<PAGE>

                                       8

     2.7  Key Investigators.  If *** employment with Xenogen Cranbury ends for
          -----------------
any reason and the parties are unable to agree on a successor reasonably
acceptable to Pfizer, Pfizer may terminate this Agreement pursuant to Section 8.

     2.8  Delays.  Any schedules or milestone dates of a party hereunder shall
          ------
be extended to: (i) account for any delays in obtaining information, or
materials from the other party which are not caused by any fault of such party;
and (ii) account for any modifications to the Research Plan which affect
schedules or milestone dates.  To the extent that any such delays or
modifications are projected to impose additional costs on one of the parties,
both Xenogen Cranbury and Pfizer shall mutually agree on the reimbursement due
on account of such additional costs.  Notwithstanding the foregoing, to the
extent that the non-delaying party accrues labor and other resource costs which
remain idle with respect to the Research Program due to such delays, the non-
delaying party shall be entitled to reimbursement from the other party for such
documented cost of such idled resources.

3.   PAYMENTS
     --------

     3.1  Research Program Funding.  In consideration for its performance of the
          -------------------------
Research Program, Pfizer will pay Xenogen Cranbury up to *** upon receipt of
invoice from Xenogen Cranbury, payable as follows:

     (a)  Within thirty (30) days of the execution of this Agreement, a fee of
          *** to be utilized for staffing, administrative and equipment
          acquisition costs over and above normal on going expenses;

     (b)  Within thirty days of the execution of the Agreement, a fee of *** to
          be utilized for Start-UP Costs;

     (c)  On the first business day of each calendar quarter during the first
          and second years of this Agreement, a payment of  *** against Xenogen
          Cranbury's invoice for such calendar quarter for work to be performed
          and costs to be incurred in such calendar quarter;

     (d)  On the first business day of each calendar quarter during the third
          year of this Agreement, a payment of *** against Xenogen Cranbury's
          invoice for such calendar quarter work to be performed and costs to be
          incurred in such calendar quarter;

     (e)  During the third year of this Agreement, payments aggregating up to
          *** in equal quarterly installments, due on the first business day of
          each quarter, against Pfizer's receipt from Xenogen Cranbury during

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       9

          that year of quarterly reports containing Results achieved pursuant to
          the Request Plan, including detailed data regarding the phenotypic
          analysis of Transgenic Animals and Xenogen Cranbury's invoice for such
          report; and

     (f)  Up to *** against delivery by Xenogen Cranbury to Pfizer of protocols
          for Track I and Track II Assays, as described in the Research Plan
          attached hereto, as the same may be amended by the parties, of which
          sum *** shall be payable upon Xenogen Cranbury's completion of Phase
          1B of Track I and initiating the testing of Control Animals in Track I
          Assays, the protocols for which Xenogen Cranbury shall have prepared
          and submitted to Pfizer for its approval (such approval not to be
          unreasonably withheld); and the remaining *** shall be payable upon
          Xenogen Cranbury's completion of Phase 1B of Track II and initiating
          the testing of Control Animals in Track II Assays, the protocols for
          which Xenogen Cranbury shall have prepared and submitted to Pfizer for
          its approval (such approval not to be unreasonably withheld).

     (g)  At Pfizer's option, it may be extend this Agreement for two successive
          one-year periods by providing 90 days' prior written notice to Xenogen
          Cranbury.

     (h)  If during the term of this Agreement Pfizer requests Xenogen Cranbury
          to perform phenotypic analysis on Transgenic Animals in addition to
          those Trangenic Animals identified in the Research Plan, Xenogen
          Cranbury will perform such services, allocating its capacity to
          perform such services for Pfizer on a priority basis, to the extent it
          is reasonably able to do so, consistent with Xenogen Cranbury's
          existing and anticipated contractual commitments. Such services shall
          be priced at the same rate as reflected in the Research Plan.

     3.2  Payment.  All payments by Pfizer under this Agreement shall be paid in
          -------
U.S. currency and shall be non-refundable.  Pfizer shall make such payments in
such form and to an account as specified by Xenogen Cranbury's invoices.

     3.3  Records.  Xenogen Cranbury shall keep for three (3) years from the
          -------
conclusion of each calendar year complete and accurate records of its costs and
expenses incurred hereunder.  The records shall conform to good accounting
principles as applied to a similar company similarly situated.  Pfizer shall
have the right, at its own expense, during the term of this Agreement and during
the

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

                                       10

subsequent three-year period to appoint an independent certified public
accountant reasonably acceptable to Xenogen Cranbury to inspect said records to
verify the accuracy of such expenditures of efforts, pursuant to each Research
Plan. Upon reasonable notice by Pfizer, Xenogen Cranbury shall make its records
available for inspection by the independent certified public accountant during
regular business hours at the place or places where such records are customarily
kept, to verify the accuracy of the expenditures of efforts. This right of
inspection shall not be exercised more than once in any calendar year and not
more than once with respect to records covering any specific period of time. All
Xenogen Cranbury information concerning such expenditures of efforts, and all
information learned in the course of any audit or inspection, shall be Xenogen
Cranbury Confidential Information and not used or disclosed by Pfizer except to
the extent necessary for Pfizer to enforce its rights under this Agreement or to
comply with law. The failure of Pfizer to request verification of any
expenditures of efforts before or during the three-year period shall be
considered acceptance by Pfizer of the accuracy of such expenditures of efforts,
and Xenogen Cranbury shall have no obligation to maintain any records pertaining
to such report or statement beyond such three-year period. The findings of such
inspection, if any, shall be binding on the parties.

4.   TREATMENT OF CONFIDENTIAL INFORMATION
     -------------------------------------
     4.1  Confidentiality
          ---------------

          4.1.1  Except as expressly provided herein, the parties agree that,
for the term of this Agreement and for five (5) years thereafter, each party
shall protect from disclosure and shall not use for any purpose as contemplated
by this Agreement, any Confidential Information of the other party (Xenogen
Cranbury Confidential Information and Pfizer Confidential Information, as the
case may be).  Each party acknowledges that the Confidential Information of the
other party constitutes highly valuable, proprietary information which is not
publicly available.

          4.1.2  Each party shall only disclose Confidential Information of the
other party to its officers, employees or agents or those of its Affiliates to
the extent necessary for such party to perform its responsibilities under this
Agreement.  Each party shall take such actions, and shall cause its Affiliates
and sublicensees to take such action, to preserve the confidentiality of the
other party's Confidential Information as it would customarily take to preserve
the confidentiality of its own Confidential Information.  On the first to occur
of the termination or expiration of this Agreement or the other party's written
request, each party will return, within sixty (60) days, all Confidential
Information of the other party, including all copies and extracts of documents,
except for one (1) copy
<PAGE>

                                       11

which each party may keep solely to enable it to comply with its continuing
obligations under this Agreement.

          4.1.3  Each party represents and covenants that all of its employees,
and any consultants of such party participating in the Research Program with
access to Program Technology, Xenogen Cranbury Technology, Pfizer Technology,
Xenogen Cranbury Confidential Information, or Pfizer Confidential Information
are, and during the term of this Agreement shall continue to be, bound by
agreement to maintain such information in confidence and use them only for the
purposes of this Agreement.

     4.2  Use by Xenogen Cranbury of Data Relating to Level I and Level II
          ----------------------------------------------------------------
Assays Performed on Pfizer Control Animals.  At any time, Xenogen Cranbury may
------------------------------------------
disclose to Third Parties results of Level I and Level II Assays performed on
Control Animals, provided that under no circumstances shall such disclosure
contain any information relating to any Pfizer Compounds, including Results
derived from animals tested with Pfizer Compounds.

     4.3  Use By Pfizer of Data Relating to Level II Assays Performed on Control
          -------------------------------------------------------------- -------
Animals of Third Parties.  During the term of this Agreement, if Xenogen
------------------------
Cranbury uses any Level II Assays to perform Contract Research Services, it will
make available to Pfizer at no charge and in a reasonably timely manner a copy
of the report containing the results of such Level II Assays (a) as such results
pertain to control animals used in such Level II Assays, (b) to the extent that
the Third Party does not prohibit Xenogen Cranbury from providing such
information and (c) subject to Pfizer agreeing to use such information only for
internal research purposes.

     4.4  Publicity.  Except as required by law, and except for a mutually
          ---------
approved press release to be issued upon signing of this Agreement, neither
party may disclose the terms of this Agreement nor the research described in it
without the written consent of the other party, which consent shall not be
unreasonably withheld; provided, however, that Xenogen Cranbury may disclose the
terms, or provide copies of this Agreement as necessary in the normal course of
business to bankers, investors and others to obtain financing.

     4.5  Disclosure Required by Law.  If either party is required by law to
          ---------------------------
disclose any Confidential Information of the other party, in connection with a
legal or administrative proceeding, such party will promptly notify the other
party in writing of such requirement or request. If the party whose Confidential
Information is the subject of such requested disclosure seeks appropriate
protective orders or other remedies to prevent or limit such disclosure, the
other party will cooperate with such effort. If the party whose Confidential
Information is the
<PAGE>

                                       12

subject of such requested disclosure fails to obtain such remedy, or provides
the other party with a written waiver of its confidentiality obligations
regarding the Confidential Information covered by such legal requirement or
request, then the other party may comply with such requirement or request by
disclosing only such portion of Confidential Information as its legal counsel
determines it is required to disclose.

     4.6  Disclosure of Inventions.  If, in the course of performing the
          ------------------------
Research Program, any employee or consultant of either party makes any invention
within Program Technology, then such party shall promptly inform the other of
such invention.  Xenogen Cranbury shall cooperate with Pfizer, at Pfizer's
expense, to prosecute and protect any patents or other intellectual property
rights in such invention.  Such cooperation shall include without limitation
identification of all inventors and assignment by all inventors of patent or
other rights to Pfizer in such invention.

     4.7  Publication. Notwithstanding this Agreement's provisions regarding
          -----------
confidentiality, results obtained in the course of the Research Program may be
submitted for publication only after scientific review by the Research Committee
and subsequent approval by management of both Xenogen Cranbury and Pfizer, who's
approval or disapproval shall be given within thirty (30) days of their receipt
of manuscripts and within fourteen (14) days of their receipt of an abstract for
presentation at, or inclusion in the proceedings of a scientific meeting, or for
a transcript of an oral presentation to be given at a scientific meeting.

5.   INTELLECTUAL PROPERTY RIGHTS
     ----------------------------

     5.1  Ownership. Xenogen Cranbury Technology shall be owned by Xenogen
          ---------
Cranbury.  All Pfizer Technology and Program Technology made in connection with
the Research Program shall be owned by Pfizer.

     5.2  Licenses to Pfizer.
          ------------------

          5.2.1  Subject to the terms and conditions of this Agreement, Xenogen
Cranbury grants to Pfizer a perpetual, worldwide, non-exclusive, royalty-free
license to make and use, but not to sell, Xenogen Cranbury Technology (i) for
Pfizer to perform the Research Program, and (ii) to the extent necessary for
Pfizer to use the Program Technology.

          5.2.2  Subject to the terms and conditions of this Agreement, Xenogen
Cranbury grants to Pfizer a perpetual, worldwide, non-exclusive, royalty-free
license, without the right to sublicense, to make and use, but not to sell the
Level IIIXC Assays.  In addition, Pfizer may use the Level IIIXC Assays with
Third
<PAGE>

                                       13

Parties provided only that Pfizer shall own all and any intellectual property
resulting from such use.

     5.3  Licenses to Xenogen Cranbury
          ----------------------------

          5.3.1   Subject to the terms and conditions of this Agreement, Pfizer
grants to Xenogen Cranbury a worldwide, non-exclusive, royalty-free license to
make and use, but not to sell Pfizer Technology (i) for Xenogen Cranbury to
perform the Research Program, and (ii) to the extent necessary for Xenogen
Cranbury to use the Program Technology within the scope of the license granted
in 5.3.2.

          5.3.2  Subject to the terms and conditions of this Agreement, Pfizer
grants to Xenogen Cranbury a worldwide, perpetual, non-exclusive, royalty-free
license, without the right to sublicense, to make, use, and sell Program
Technology, other than Level IIIP Assays. For the avoidance of doubt, pursuant
to this Section 5.3.2 Pfizer agrees that Xenogen Cranbury may disclose to Third
Parties, any and all protocols relating to the Program Technology (other than
Level IIIP Assays) in connection with Xenogen Cranbury's performance of Contract
Research Services for Third Parties.

          5.3.3  Subject to the terms and conditions of this Agreement, Pfizer
grants to Xenogen Cranbury a perpetual worldwide, non-exclusive, royalty-free
license, without the right to sublicense, to make, use, and sell Level IIIP
Assays to perform Contract Research Services after the Period of Exclusivity.
For the avoidance of doubt, pursuant to this Section 5.3.3 Pfizer agrees that
Xenogen Cranbury may disclose to Third Parties, any and all protocols relating
to the Level IIIP Assays in connection with Xenogen Cranbury's performance of
Contract Research Services for Third Parties after the Period of Exclusivity.

6.   ACQUISITION OF RIGHTS FROM THIRD PARTIES
     ----------------------------------------

     During the Contract Period, Xenogen Cranbury and Pfizer shall each promptly
notify each other of any appropriate opportunities to acquire in any manner from
third parties, technology or patents or information which it proposes to use in
the course of performing the Research Program.  Xenogen Cranbury and Pfizer
shall discuss if such rights should be acquired in connection with the Research
Program and, if so, whether by Xenogen Cranbury, Pfizer or both and how the
costs for such acquisition should be allocated, it being understood that nothing
herein shall obligate either party to obtain such rights or, if it does acquire
such rights, to make such rights available for use in the Research Program.
<PAGE>

                                       14

7.   OTHER AGREEMENTS
     ----------------

     This Research Agreement, together with its Exhibits, sets forth the entire
agreement between the parties with respect to the subject matter and supersede
all other agreements and understandings between the parties with respect to
same.

8.   TERM, TERMINATION AND DISENGAGEMENT
     -----------------------------------

     8.1  Term.  Unless sooner terminated as provided below or extended by
          ----
mutual agreement of the parties, this Agreement shall expire on December 28,
2003.

     8.2  Events of Termination.  The following events shall constitute events
          ---------------------
of termination ("Events of Termination"):

          (a)  if any written representation or warranty by Xenogen Cranbury or
Pfizer, made in Section 9.1 shall prove to have been incorrect in any material
respect when made; and

          (b)  Xenogen Cranbury or Pfizer shall fail in any material respect to
perform or observe any term, covenant or understanding contained in this
Agreement or in any of the other documents or instruments delivered pursuant to,
or concurrently with, this Agreement, and any such failure shall remain
unremedied for thirty (30) days after written notice to the failing party.

          Except as provided in Section 8.2(b), upon the occurrence of any Event
of Termination, the party not responsible may, by written notice to the other
party, terminate this Agreement.

     8.3  Effects of Termination.
          ----------------------

          8.3.1     Termination of this Agreement by either party pursuant to
Section 8.2 will not terminate the confidentiality obligations and the
exclusivity and licenses pursuant to Section 4.1, 5.2 and 5.3.

          8.3.2     In the event of termination by either party pursuant to this
Section 8, neither party shall be liable to the other because of such
termination, for compensation, reimbursement of damages on account of the loss
of prospective profits, of anticipated sales or on account of expenditures,
inventory, investments, leases or commitments in connection with the business or
goodwill of Xenogen Cranbury or Pfizer.
<PAGE>

                                       15

          8.3.3     Notwithstanding the foregoing Section 8.3.2, termination of
this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the
other party or which is attributable to a period prior to such termination nor
preclude either party from pursuing any rights and remedies it may have
hereunder or at law or in equity with respect to any breach of this Agreement,
including without limitation Xenogen Cranbury's right to receive all payments
accrued under Section 3.

9.   REPRESENTATIONS AND WARRANTIES; LIMITATION OF LIABILITY
     -------------------------------------------------------

     9.1  Representations, Warranties and Covenants.  Xenogen Cranbury and
          -----------------------------------------
Pfizer each represents and warrants as follows:

          9.1.1  It is a corporation duly organized, validly existing and is in
good standing under the laws of the States of Ohio and Delaware, respectively,
is qualified to do business and is in good standing as a foreign corporation in
each jurisdiction in which the conduct of its business or the ownership of its
properties requires such qualification; and it has all requisite power and
authority, corporate or otherwise, to conduct its business as now being
conducted, to own, lease and operate its properties and to execute, deliver and
perform this Agreement.

          9.1.2  The execution, delivery and performance by it of this Agreement
have been duly authorized by all necessary corporate action and do not and will
not (a) require any consent or approval of its stockholders beyond the approvals
already obtained, (b) violate any provision of any law, rule, regulations,
order, writ, judgement, injunction, decree, determination or award presently in
effect having applicability to it or any provision of its certificate of
incorporation or by-laws or (c) result in a breach of or constitute a default
under any material agreement, mortgage, lease, license, permit or other
instrument or obligation to which it is a party or by which it or its properties
may be bound or affected.

          9.1.3  This Agreement is a legal, valid and binding obligation of it
enforceable against it in accordance with its terms and conditions, except as
such enforceability may be limited by applicable bankruptcy, insolvency,
moratorium, reorganization or similar laws, from time to time in effect,
affecting creditor's rights generally.

          9.1.4  It is not under, and will not enter into, any obligation to any
person, or entity, contractual or otherwise, that is conflicting or inconsistent
in any respect with the terms of this Agreement or that would impede the
diligent and complete fulfillment of its obligations.
<PAGE>

                                       16

          9.1.5  It has the right, power and title to enter into this Agreement
and grant the rights and licenses and/or sublicenses granted herein.

     9.2  Disclaimer of Warranties.  EXCEPT FOR THE EXPRESS WARRANTY SET FORTH
          ------------------------
ABOVE IN SECTION 9.1, NEITHER XENOGEN CRANBURY NOR PFIZER MAKES ANY OTHER
WARRANTIES (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE
XENOGEN CRANBURY TECHNOLOGY, PFIZER TECHNOLOGY, AND PROGRAM TECHNOLOGY, AND
SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES OF NONINFRINGEMENT OF THIRD
PARTY INTELLECTUAL PROPERTY RIGHTS.

     9.3  LIMITATION OF LIABILITY.  IN NO EVENT SHALL EITHER PARTY BE LIABLE TO
          -----------------------
THE OTHER OR ANY OTHER ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR
INDIRECT DAMAGES, UNLESS SUCH PARTY DEMONSTRATES THAT THE OTHER PARTY'S BREACH
CONSTITUTED WILLFUL MISCONDUCT OR GROSS NEGLIGENCE.

     9.4  Covenants.  Throughout the Contract Period, Xenogen Cranbury and
Pfizer each shall:

          9.4.1  maintain and preserve its corporate existence, rights,
franchises and privileges in the jurisdiction of its incorporation, and qualify
and remain qualified as a foreign corporation in good standing in each
jurisdiction in which such qualification is from time to time necessary or
desirable in view of their business and operations or the ownership of their
properties; and

          9.4.2  comply in all material respects with the requirements of all
applicable laws, rules, regulations and orders of any government authority to
the extent necessary to conduct the Research Program, except for those laws,
rules, regulations, and orders it may be contesting in good faith.

10.  INDEMNIFICATION
     ---------------

     Pfizer and Xenogen Cranbury each will indemnify, defend and hold each other
harmless for any and all damages, settlements, costs, legal fees and other
expenses incurred in connection with a claim by a third party against either
party based on any action or omission of the indemnifying party's agents,
employees, or officers related to its obligations under this Agreement;
provided, however, that the foregoing shall not apply (i) if the claim is found
to be based upon the gross
<PAGE>

                                       17

negligence, recklessness or willful misconduct of the party seeking
indemnification; or (ii) if such party fails to give the other party prompt
notice of any claim it receives and such failure materially prejudices the other
party with respect to any claim or action to which its obligation pursuant to
this Section applies. Notwithstanding the foregoing, Pfizer hereby expressly
agrees to indemnify, defend and hold harmless Xenogen Cranbury (and all
officers, directors, agents and Affiliates of Xenogen Cranbury) for any and all
claims arising from clinical trials pursued by Pfizer or its Affiliates and/or
sublicensees, the exercise of rights granted to Pfizer under Section 5.2 and/or
claims arising from patent rights, Pfizer patent rights, Program Technology and
Pfizer Technology except for intellectual property claims with respect to
Xenogen Cranbury patent rights, or Xenogen Cranbury Technology. The indemnifying
party agrees to pay, subject to the limitations set forth herein, any final
judgement entered against the indemnified party on such issue in any such claim
defended by the indemnifying party. Each party shall cooperate with the other
during the course of such a claim, and the indemnifying party shall keep the
indemnified party(ies) reasonably informed of the progress and status of the
claim. The indemnifying party, in its sole discretion, shall choose legal
counsel, shall control the defense of such claim or action and shall have the
right to settle same on such terms and conditions it deems advisable.

11.  NOTICES
     -------

     All notices shall be in writing mailed via certified mail, return receipt
requested, courier, or facsimile transmission addressed as follow, or to such
other address as may be designated from time to time:

     If to Pfizer:            Pfizer Global Research & Development
                              Eastern Point Road
                              Groton, CT 06340
                              Attention:  President of Strategic Operations -
                              PGRD-Groton
                              copy to: Assistant General Counsel - PGRD - Groton

     If to Xenogen Cranbury:  Xenogen Biosciences
                              5 Cedar Brook Drive
                              Cranbury, NJ 08512

         with a copy to:      Xenogen Corporation
                              860 Atlantic Avenue
<PAGE>

                                       18

                              Alameda, CA  94501
                              Attn:  General Counsel

Notices shall be deemed given as of the date received at the above specified
address.

12.  GOVERNING LAW
     -------------

     This Agreement shall be governed by and construed in accordance with the
laws of the State of New Jersey, without reference to its conflict of laws
rules.  The U.N. Convention for the Sale of Goods shall not apply. The exclusive
venue of any dispute arising out of or in connection with the performance or
breach of this Agreement shall be the New Jersey state courts located in
Middlesex County, New Jersey or the U.S. district court for the District of New
Jersey.

13.  MISCELLANEOUS
     -------------

     13.1 Binding Effect.  This Agreement shall be binding upon and inure to the
          --------------
benefit of the parties and their respective legal representatives, successors
and permitted assigns.

     13.2 Headings.  Paragraph headings are inserted for convenience of
          --------
reference only and do not form a part of this Agreement.

     13.3 Counterparts.  This Agreement may be executed simultaneously in two or
          ------------
more counterparts, each of which shall be deemed an original.  Signatures may be
transmitted via facsimile, thereby constituting the valid signature and delivery
of this Agreement.

     13.4 Amendment, Waiver.  This Agreement may be amended, modified,
          -----------------
superseded or cancelled, and any of the terms may be waived, only by a written
instrument executed by each party or, in the case of waiver, by the party or
parties waiving compliance.  The delay or failure of any party at any time or
times to require performance of any provisions shall in no manner affect the
rights at a later time to enforce the same.  No waiver by any party of any
condition or of the breach of any term contained in this Agreement, whether by
conduct, or otherwise, in any one or more instances, shall be deemed to be, or
considered as, a further or continuing waiver of any such condition or of the
breach of such term or any other term of this Agreement.

     13.5 No Third Party Beneficiaries.  No third party including any employee
          ----------------------------
of any party to this Agreement shall have or acquire any rights by reason of
this
<PAGE>

                                       19

Agreement. Nothing contained in this Agreement shall be deemed to constitute the
parties partners with each other or any third party.

     13.6 Assignment and Successors.  This Agreement may not be assigned by
          -------------------------
either party, except that each party may assign this Agreement and the rights
and interests of such party, in whole or in part, to any of its Affiliates, any
purchaser of all or substantially all of its assets related to the subject
matter of this Agreement, or to any successor corporation resulting from any
merger or consolidation of such party with or into such corporations.

     13.7 Force Majeure. Neither Pfizer nor Xenogen Cranbury shall lose any
          -------------
rights hereunder or be liable to the other for damages or losses (except for
payment obligations) on account of failure of performance by the defaulting
party if the failure is occasioned by war, strike, fire, Act of God, earthquake,
flood, lockout, embargo, governmental acts or orders or restrictions, failure of
suppliers, or any other reason where failure to perform is beyond the reasonable
control, and not caused by the negligence, intentional conduct or misconduct, of
the nonperforming party and the nonperforming party has exerted all reasonable
efforts to avoid or remedy such force majeure; provided, however, that in no
event shall a party be required to settle any labor dispute or disturbance.

     13.8 Severability.  If any provision of this Agreement is or becomes
          ------------
invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the parties that the remainder of the
Agreement shall not be affected so long as the essential benefits of this
Agreement remain enforceable and obtainable.
<PAGE>

                                       20

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives.

PFIZER INC                                       XENOGEN BIOSCIENCES

By:/s/ George M. Milne, Jr.       By: /s/ Pamela Reilly Contag
   ------------------------           ------------------------

Name:  George M. Milne, Jr.       Name:   Pamela Reilly Contag

Title: Senior Vice President      Title:  President
<PAGE>

                                       21

                                   EXHIBIT A

                                      ***

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       22

                                   EXHIBIT B

                                      ***

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       23

                                   EXHIBIT C

                                      ***
________________________
***CONFIDENTIAL TREATMENT REQUESTEDExhibit 10.1

        Exhibit
10.1 Agreement between the Registrant and Auerbach, Pollak & Richardson,
dated December 12, 2000. 

SHARE
PURCHASE AGREEMENT

This SHARE PURCHASE AGREEMENT
(“Agreement”), dated as of December 12, 2000 (the “Closing
Date”), is entered into by eVision USA.Com, Inc., a Colorado corporation
(“eVision”), American Fronteer Financial Corporation, a Colorado
corporation and wholly owned subsidiary of eVision (“AFFC”)(AFFC and
eVision may be hereinafter referred to as “Buyer”), and Auerbach,
Pollak, and Richardson, Inc., a Delaware corporation (“APR” or
“Seller”)(all parties may be collectively referred to as
“Parties”) 

        WHEREAS,
AFFC and APR are registered securities broker/dealers which, among other
activities, provide customary broker/ dealer services to retail and
institutional clients through a network of branch offices; and

        WHEREAS,
eVision desires to purchase shares, representing a certain percentage, of APR,
and APR desires to sell those shares to eVision.

        NOW
THEREFORE, in consideration of the terms, conditions, and covenants herein contained, the parties
hereby agree as follows:

1.0   TRANSFERS

        1.01
Transfer of Shares. Upon the transaction date of December
19th, 2000 (“Transaction Date”), Seller shall deliver to
eVision: 

	 	
(a)
such number of shares, with preemptive rights, as will equal, after giving
effect to the issuance thereof, 24.9% (twenty-four and nine tenths percent) of
the outstanding common stock of APR, on a fully diluted basis prior to an
initial public offering, issued and outstanding as of the execution date; and

	 	
(b)
an option to purchase an additional 15.1% (fifteen and one tenth percent) of
outstanding common stock, with preemptive rights, on a fully diluted basis prior
to an initial public offering, of APR for one dollar. Such option shall expire
two years after the date of execution of this Agreement.

	 	
(c)
A right of first refusal to match future equity financing of APR, exercisable
for thirty (30) days after written presentation to eVision of any proposed
equity financing for APR.

        1.02
Instruments of Conveyance and Transfer. Upon the execution of this
Agreement, the Parties agree to execute and deliver to the other party such
documents of transfer that the Parties may reasonably request relating to the
shares acquired by this Agreement.

2.0  PURCHASE PRICE,
ASSUMPTION OF LIABILITIES

        2.01
Purchase Price. As consideration, Buyer shall convey, transfer, or assign to
Seller, the certain assets and certain personnel of AFFC relating to its retail
brokerage and other operations in Albany, NY; Chicago, IL; Atlanta, GA; Dallas,
TX; Colorado Springs, CO; San Francisco, CA; and in the Denver, CO Headquarters,
and more specifically listed in SCHEDULE A, (hereinafter collectively referred
to as the “Assets”). APR shall have the right to reasonably reject or
renegotiate all contracts, agreements or commitments of any kind within a
reasonable period after consummation of this Agreement. Any transfer of leases
and contracts, as requested, by APR pursuant to this Agreement, will be
completed in a reasonably timely manner. Any equipment or leasehold improvements
owned by AFFC, in locations accepted by APR, will become property of APR, if not
excluded, by APR. It is understood that there can be no guarantee that employees
of AFFC may elect to become employees of Seller, and that those employees who do
elect to be employed by Seller will become “at-will” employees of
Seller. 

        In
addition:

	 	
(a)
All commissions, including but not limited to gross credits, mutual fund
trailers, 12(b)(1) revenue, and miscellaneous broker/dealer revenue, and all
commission expense responsibility, of AFFC for the month of December 2000, shall
be transferred to APR no later than January 10, 2001.

	 	
(b)
APR will be responsible for the pro rata share of the operating expenses of the
Assets after the Transaction Date, and shall reimburse AFFC for these expenses
it accepts, no later than January 19, 2001.

	 	
(c)
It is understood that the Parties will meet no later than the 15th of
the subsequent months to reconcile outstanding balances.

        2.02
Instruments of Conveyance and Transfer. Upon the execution of this
Agreement, the Parties agree to execute and deliver to the other party such
documents of transfer that the Parties may reasonably request relating to the
Assets acquired by this Agreement. 

        2.03
Assumption of Liabilities. APR is not assuming, and shall not be deemed to
have assumed, any liabilities or obligations of eVision or AFFC.

3.0   BOARD REPRESENTATION

        3.01
Upon the execution of this Agreement, Seller shall give to eVision the option to
nominate two members to the Board of Directors of APR whose elections shall not
be unduly withheld. 

4.0   REPRESENTATIONS AND
WARRANTIES

        4.01
Representations and Warranties of Parties. The Parties represent and warrant to
the other party as follows:

2

        
(a) Organization, Corporate Power. Each Party is a corporation duly
organized, validly existing and in good standing under the laws of the
jurisdiction of its corporation. The Parties have all requisite corporate power
and authority to own, operate and lease the Assets, to carry on the operations
as it is now being conducted, to execute and deliver this Agreement and to
perform their obligations hereunder. 

        
(b) Marketable Title. To the best of its knowledge, AFFC has good and
marketable title to the Assets, free and clear of any and all liens, charges,
claims, pledges, security interests or other encumbrances of any kind
whatsoever, except for any obligations that accompany certain Assets that arise
in the ordinary course of business, including but not limited to lease
obligations. 

        
(c) Record Owner. eVision is the record and beneficial owner of all of the
outstanding shares of capital stock of AFFC.

        
(d) Condition of the Assets. The Assets conform in all respects to
all requirements of applicable laws. All of the Assets are in good operating
condition and in good state of maintenance and repair and are adequate for use
in the conduct of AFFC’s business as previously conducted. 

        
(e) Authorization; Validity of Agreement. Parties have the full right, power
and authority, to execute and deliver this Agreement to which it is a party and
to consummate the transactions contemplated hereby, and to make the
representations set forth herein and therein. The execution and delivery of this
Agreement and the consummation of the transactions contemplated hereby have been
duly and validly authorized by the Parties and no other proceedings on the part
of the Parties are necessary to authorize the execution and delivery of this
Agreement or the consummation of the transactions contemplated hereby by the
Parties. This Agreement will be duly and validly executed by the Parties and
constitute the valid and binding agreement of the Parties, enforceable against
Buyer in accordance with its respective terms, except as such enforceability may
be subject to or limited by applicable bankruptcy, insolvency, reorganization or
other similar laws affecting the enforcement of creditors’ rights
generally. 

        
(f) Consents and Approvals; No Violation. The execution, performance and
delivery by Parties of this Agreement and the consummation by Parties of the
transactions contemplated hereby and thereby, respectively, and the compliance
by Parties with the provisions hereof will not: (a) conflict with or breach any
provision of the Articles of Incorporation or By-Laws of the Parties; (b)
violate or breach in any respect any provision of, or constitute a default (or
an event which, with notice or lapse of time or both would constitute a default)
under, any of the terms, covenants, conditions or provisions of, or give rise to
a right to terminate or accelerate or increase the amount of payment due under,
any note, bond, mortgage, indenture, deed of trust, license, franchise, permit,
lease, contract, agreement or other instrument, commitment or obligation to
which Parties are a party (collectively, “Contracts”), or by
which Parties or any of its properties or assets, as applicable, may be bound or
affected; (c) result in the creation of any Lien on or affecting the Assets; (d)
violate any order, writ, injunction, decree, judgment, or ruling of any court or
governmental authority, applicable to Buyer or any of their respective
properties or assets; or (f) violate any statute, law, rule or regulation
applicable to Parties or any of its properties or assets. 

3

        
(g) Governmental Consents. To the best of the Buyer’s knowledge, no
consent, permit, license, order, appointment, franchise, certificate, approval
or authorization of, or registration, declaration or filing with, any foreign,
federal, state or local court, administrative agency or commission or other
governmental authority or instrumentality (a “Governmental
Entity”) is required by Parties in connection with the execution and
delivery of this Agreement. 

        
(h) Litigation. AFFC agrees it shall defend, continue to defend, promptly
pay all costs and expenses including legal fees, settlements, and judgments and
indemnify APR from any litigation that AFFC is currently defending. AFFC shall
defend, continue to defend, continue to promptly pay all costs and expenses
including legal fees settlements and judgments, and indemnify costs and expenses
including legal fees, settlements and judgments of future litigation that arise
from the business activities of AFFC or eVision, prior to the execution of this
transaction. APR agrees that it will reasonably cooperate, including but not
limited to providing access to employees and documents, with AFFC and eVision in
its resolution of its litigation matters. 

        
(i) Investment Intent; Right of First Refusal. eVision is acquiring the
shares of common stock of APR for its own account, for investment purposes and
not with a view to, or for sale in connection with, any distribution. eVision
may transfer its interest to an affiliate with the written consent of APR, which
shall not be unreasonably withheld. eVision and APR agree to enter into a
Shareholder’s Agreement whereby APR retains a right of first refusal,
exercisable for sixty days after eVision’s written notice of intent to
sell, to purchase, or arrange for the purchase, of eVision’s interest. 

        
(j) Accredited Investors. eVision: (i) is an “accredited investor”
as that term is defined in Rule 401(a) promulgated under the Securities Act of
1933, as amended (the “Act”), (ii) is able to sustain an entire
loss of the investment represented by the Shares, (iii) has such knowledge and
experience in financial, business and investment matters as to be capable of
evaluating the merits and risks of this investment, (iv) has the ability to bear
the economic risks of this investment, (v) has had access to and has received
such information regarding APR as is specified in subparagraph (b)(2) of Rule
402 promulgated under the Act, and (vi) without in any way limiting APR’s
right or ability to rely on the representations and warranties made by Buyer in
or pursuant to this Agreement, has been afforded prior to the closing the
opportunity to ask questions of, and to receive answers from, APR and to obtain
any additional information, to the extent APR has such information or could have
acquired it without unreasonable expense, all as necessary for eVision to make
an informed investment decision with respect to the acquisition of the Shares. 

4

        
(k) Authorization of Agreements. All Parties state that the execution of
this transaction has been authorized by requisite corporate action.

        
(l)    Financial Statements; Reports.

	 	 	 	1.	
AFFC and APR have submitted, and will continue to submit upon request by the
other party, accurate and current financial statements to the other Party.

	 	 	 	2.	
Each of the Parties has filed all: (i) forms, reports, statements and other
documents required to be filed with the SEC including, without limitation, all
FOCUS reports and all amendments and supplements to all such reports; and (ii)
forms, reports, statements and other documents required to be filed with any
Governmental Authorities.

        
(m) Registrations. AFFC and APR are duly registered as a broker/dealer and
such registrations are in full force and effect.

        
(n) Employee Registrations. All of APR’s officers and employees and all
of AFFC’s officers and employees who are required to be licensed or
registered to conduct the business of APR and AFFC, respectively, as presently
conducted are duly licensed or registered in each state in which such licensing
or registration is so required. 

        
(o) Common Stock of APR. As of the date hereof, the authorized Common Stock
of APR consists of ____shares of common stock, par value $_______per share, of
which ________shares are outstanding as of the date hereof. 

        
(p) Other Information. None of the information furnished by Parties to the
other party in this Agreement, the exhibits hereto, the schedules identified
herein, or in any certificate or other document to be executed or delivered
pursuant hereto by Parties at or prior to the execution, is, or upon the
execution will contain, any misstatement of material fact. 

        
(q) Notifications. The Parties shall promptly notify the other party in
writing:

	 	 	 	1.	
of any governmental, administrative or Self Regulatory Organization complaints,
investigations or hearings (or communications indicating that the same may be
contemplated) related to its business; and

	 	 	 	2.	
if either Party shall discover that any representation or warranty made by them
in this Agreement was when made, or has subsequently become, untrue in any
respect;

5

	4.02	
Confidentiality. The contents of this Agreement shall be kept confidential
between the Parties, except as otherwise required by law, including but not
limited to the provisions of the federal securities laws, and except that each
party may discuss the contents with its professional advisors, including
attorneys and accountants. 

	4.03	
Insurance. The Parties shall continue current insurance arrangements
until there can be further agreement between the parties as to appropriate
insurance coverage.

4.04 Retention
of Employees; Benefits.

	 	        
(a) Offers of Employment. Effective reasonably after the execution date, APR
may offer to continue the employment, at will, or consultancy of all employees.
AFFC shall notify APR if any employee of, or consultant to, AFFC shall announce
his or her intention not to accept such offer by APR. Upon the employee(s)’
acceptance of employment with APR, their forgivable loan, if applicable, shall
be transferred and/or assigned to APR. APR shall not be responsible for any
payments, expenses and costs paid or required to be paid in connection with the
employment or termination of employment of any employees of Buyer who do not
accept APR’s offer of employment with APR. 

	 	        
(b) No Contract Offer of Employment. Nothing in this Agreement, express or
implied, shall confer upon any employee of Parties, or any representative of any
such employee, any rights or remedies, including any right to employment or
continued employment for any period, of any nature whatsoever, whether as a
third party beneficiary or otherwise, it being understood and agreed that any
such employment shall, to the maximum extent permitted by applicable law, be
employment at will. 

	 	        
(c) Worker Adjustment and Retraining Notification Act of 1988. If
applicable, pursuant to the Worker Adjustment and Retraining Notification Act of
1988 (“WARN”), Buyer has provided or shall provide timely and
effective notice to its employees and any applicable unit of government with
respect to any employment loss suffered by such employees as the result of the
termination of their employment by Buyer and any failure of APR to employ them
at the Closing. Nothing contained in this Section ____ shall be deemed to
constitute a requirement that APR employ or offer employment to such employees.
In the event that WARN requires notice to such employees and Buyer fails to
provide timely and effective notice under WARN, Buyer shall indemnify and hold
APR harmless from and against any liability to such employees or any unit of
government that may result to APR from such failure, including but not limited
to, fines, back pay and reasonable attorney’s fees. 

	 	        (d)
Buyer shall remain responsible for costs and expenses that relate to its
employees and arose prior to this Agreement including: (i) payment of any and
all wages, accrued vacation pay, bereavement pay, jury duty pay, disability
income, supplemental unemployment benefits, fringe benefits or other perquisites
of employment, termination indemnities or similar benefits (whether arising
under any plan, program, policy or arrangement of Buyer or under applicable
local law), payroll taxes and other payroll related expenses; (ii) payments to
or under employee benefit plans (within the meaning of section 3(3) of ERISA)
maintained or contributed to by Buyer, in either case arising out of or relating
to the employment of any of the Transferred Employees by Buyer prior to the
Closing Date; (iii) all workers’ compensation claims of its employees; (iv)
compliance with COBRA and ERISA; and (v) grievance, arbitration proceeding,
charge or complaint filed on behalf of an employee or labor organization, before
the National Labor Relations Board, the Equal Employment Opportunity Commission,
state and local civil rights agencies, federal or state departments of labor,
and the various occupational health and safety agencies. 

6

4.05 Further
Assurances.

	 	        
(a) Future Documents. From time to time following the execution of this
Agreement, the Parties shall execute and deliver, or cause to be executed and
delivered, to the other party such documents of conveyance and transfer, in form
reasonably satisfactory to the other party, as the other party may reasonably
request. 

	 	        
(b) Supporting Documents. Parties and their counsel shall have reasonable
access to the following supporting documents of the other Parties: copies of the
Articles of Incorporation, bylaws, resolutions, and other corporate documents of
each Party and all amendments thereto.

5.0  INDEMNITY

Notwithstanding any
investigation made by each of the parties hereto, all representations and
warranties of each of the parties in this Agreement shall survive for a period
of three (3) years from the Closing Date. 

5.01 AFFC
Indemnification. AFFC agrees to indemnify, defend, and hold APR and its
directors, officers, employees, agents and representatives harmless from and
against all demands, claims, actions or causes of action, assessments, losses,
damages, liabilities, including interest, penalties, and reasonable
attorney’s fees, assessed against, resulting to, imposed upon or incurred
by APR by reason of or resulting from: 

	 	 	(a)	
a breach of or failure to perform any representation, warranty or covenant by
AFFC contained in this Agreement;

	 	 	(b)	
any liabilities or obligations by AFFC that are not assumed by APR pursuant to
this Agreement; or

	 	 	(c)	
the ownership or operation of the Business or the Assets of AFFC as conducted
prior to the date hereof, including without limitation any failure by AFFC to
conduct its business prior to the date of execution in compliance with any
federal, state or local laws, statutes, ordinances, rules, regulations, or
permits.

5.02 APR
Indemnification. APR agrees to indemnify, defend, and hold AFFC and eVision
and their directors, officers, employees, agents and representatives harmless
from and against all demands, claims, actions or causes of action, assessments,
losses, damages, liabilities, including interest, penalties, and reasonable
attorney’s fees, assessed against, resulting to, imposed upon or incurred
by AFFC or eVision by reason of or resulting from: 

7

	 	 	(a)	
a breach or failure to perform any representation, warranty or covenant by APR
contained in this Agreement; or

	 	 	(b)	
any failure by APR to conduct its business prior to the date of execution in
compliance with any federal, state or local laws, statutes, ordinances, rules,
regulations, or permits.

6.0   TERMINATION

        6.01
Termination.  This Agreement may be terminated:

	 	
(a) by APR, if Buyer commits a material misrepresentation, fraud, or illegality,
to APR’s material detriment, of a material condition and obligation set
forth in this Agreement, and Buyer does not cure or eliminate the material
misrepresentation, fraud, or illegality (or APR does not waive same) within
thirty (30) days after written notice has been given by APR to Buyer of such
material misrepresentation, fraud, or illegality;

	 	
(b) by Buyer, if the material conditions and obligations set forth in this
Agreement have not been complied with or performed by APR.

        6.02
Effect of Termination. In the event of the termination of this agreement
pursuant Agreement, the Agreement shall thereafter become void and have no
effect, and no party shall have any liability to the other party hereto or to
its stockholders, directors or officers, except that nothing herein shall
relieve any party from liability for any willful breach of this Agreement. 

7.0   MISCELLANEOUS

        7.01
Non-Solicitation of Employees. Except with consent of APR, until the third
anniversary of the Closing Date, neither Buyer nor any affiliate of Buyer,
shall, directly or indirectly, for itself or for any other person, firm,
corporation, partnership, association or other entity, attempt to employ or
enter into any contractual arrangement with any employee or former employee of
APR, unless such employee or former employee has not been employed by APR for a
period in excess of one year. 

        7.02
Non-Competition. Except with the consent of APR, until the December
11, 2001 (the “Non Competition  Period”), neither Buyer,
nor any affiliate of Buyer, shall directly or indirectly, solicit business from
any person or entity that was a customer of Buyer at any time prior to the
Closing Date. Buyer acknowledges that the provisions of this section, and the
period of time, geographic area and scope and type of restrictions on their
activities set forth herein, are reasonable and necessary for the protection of
Seller and are an essential inducement to APR’s entering into this
Agreement to which it is a party and consummating the transactions contemplated
thereby. 

8

        7.03
Execution in Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 

        7.04
Notices. All notices that are required or may given pursuant to the terms of
this Agreement shall be in writing and shall be sufficient in all respects if
delivered by hand or via a national overnight courier service or mailed by
registered or certified mail postage prepaid, as follows: 

        If
 to Seller:  Auerbach, Pollak & Richardson, Inc.

                450
Park Avenue, 8th Floor

                New
York, NY 10022

                Attention:
Hugh Regan, President

                And
to counsel:

                Richard
Cushing, Esq.

                Parker
Chapin, LLP

                The
Chrysler Building

                405
Lexington Avenue

                New
York, NY 10174

        If
 to Buyer:  eVision USA.Com, Inc.
                1700
Lincoln Street, 32nd Floor
                Denver,
CO 80203
                Attention:
Fai Chan, President

        7.05
Waivers. Parties, may, by written notice to the other party:

	 	
(a) extend the time for the performance of any of the obligations or other
actions of the other party under this Agreement;.

	 	
(b) waive any inaccuracies in the representations or warranties of the other
party contained in this Agreement or in any document delivered pursuant to this
Agreement;

	 	
(c) waive compliance with any of the conditions or covenants of the other party
contained in this Agreement; or

	 	
(d) waive performance of any of the obligations of the other party under this
Agreement.

	 	
The
waiver by either party of a breach of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach.

        7.06
Amendments, Supplements, Etc. This Agreement may only be amended by written
document, signed by the Parties.

9

        7.07
Entire Agreement. This Agreement, and its Schedules and Amendments,
constitute the entire agreement among the parties hereto with respect to the
subject matter hereof and supersede all prior agreements and understandings,
oral and written, between the parties hereto with respect to the subject matter
hereof. No representation, warranty, promise, inducement or statement of
intention has been made by any party which is not embodied in this Agreement or
such other documents, and neither Sellers, on the one hand, nor Buyers, on the
other hand, shall be bound by, or be liable for, any alleged representation,
warranty, promise, inducement or statement of intention not embodied herein.

        7.08
Applicable Law; Jurisdiction. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York and the
jurisdiction of the courts of the State of New York.

	7.09	
Binding Effect; Benefits. This Agreement shall inure to the benefit of
and be binding upon the Parties hereto and their respective successors and
assigns. Notwithstanding anything contained in this Agreement to the contrary,
nothing in this Agreement, expressed or implied, is intended to confer on any
person other than the parties hereto or their respective successors and assigns
any rights, remedies, obligations or liabilities under or by reason of this
Agreement.

	7.10	
Assignment. Neither this Agreement nor any of the Parties’ rights
hereunder shall be assignable by any party hereto without the prior written
consent, of which shall not be unreasonably withheld, of the other party hereto.

                                  (The rest of the page left intentionally blank)

         IN WITNESS WHEREOF, this Share Purchase Agreement has been duly executed and delivered by the Parties
hereto as of the date first written.

EVISION USA.COM, INC.

By:  /s/ Jeffrey M. Busch

Title:  Director
(Subject to approval and
ratification by the Board of Directors of eVision USA.Com, Inc.) 

American Fronteer Financial Corporation

By:  /s/ Robert H. Trapp

Title:  President

AUERBACH, POLLAK, & RICHARDSON, INC.

By: /s/ Hugh Regan

Title:  Hugh Regan, President

                                                    Schedule A
                                                    ----------

The following Schedule refers to certain assets and certain personnel of the following Branch Offices and
Divisional Departments:

Albany, NY; Chicago, IL; Atlanta, GA; Dallas, TX; Colorado Springs, CO; San Francisco, CA; and in the Denver, CO
Branch, certain assets and personnel relating to Retail Sales, Compliance, Operations, Trading and Research, and
Administration)

Assets, subject to review and approval of APR, shall include:

	 	 	1.	
Any tangible property, equipment, supplies, computer equipment, spare parts,
furniture and office furnishings, to the extent that such assets are designated
by APR.

	 	 	2.	
Any registrations with, or licenses granted by, any governmental authority or
Self Regulatory Authority, to the extent such registrations and licenses are
transferable and are necessary or desirable to APR in order for APR to be able
to continue to conduct certain operations.

	 	 	3.	
To the extent requested by APR, copies of all papers, documents, instruments,
books and records, files, agreements, books of account and other records by
which any of the Assets might be identifies or enforced, or otherwise pertaining
to the Assets, used in connection with the assets, and including client
invoices, client lists, vendor and supplier lists and other documents relating
to customer transactions.

4.       The rights and obligations of AFFC under certain leases, contracts, agreements, and other commitments
                 relating to the Assets.

                a.       General lease obligations including, but are not limited to, office space, copiers, computer equipment,
                          and postage meters.

                b.       Contract obligations including, but are not limited to, forgivable loans.

Excluded Assets shall
include: Stock, cash, marketable securities, and warrants held by AFFC. 

Accepted by:

/s/ Hugh Regan                              /s/ Jeffrey M. Busch
Auerbach, Pollak, & Richardson              eVision USA.Com, Inc.

/s/ Robert H. Trapp
American Fronteer Financial Corporation

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]